TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced a board meeting scheduled for October 30, 2025, to review and approve the company’s third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the development and manufacturing of heparin products and other related pharmaceutical services.
Average Trading Volume: 2,697,658
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.23B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.